as of 11-20-2026 3:45pm EST
Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on turning scientific promise to makes a difference for underserved neurological and rare disease communities around the world. It has two core franchises in neurological and rare diseases. Its neurological disease is anchored by the commercial product NUPLAZID (pimavanserin), which is the first and only drug approved by the U.S. (FDA) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis (PDP). Its rare disease is anchored by the commercial product DAYBUE, which is the first and only drug approved for the treatment of Rett syndrome. Its clinical-stage development efforts are focused on Alzheimer's disease psychosis, Lewy Body Dementia psychosis, and multiple other programs.
| Founded: | 1993 | Country: | United States |
| Employees: | N/A | City: | SAN DIEGO |
| Market Cap: | 4.4B | IPO Year: | 2000 |
| Target Price: | $30.21 | AVG Volume (30 days): | 2.4M |
| Analyst Decision: | Buy | Number of Analysts: | 20 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | 0.51 | EPS Growth: | 69.12 |
| 52 Week Low/High: | $15.86 - $30.96 | Next Earning Date: | 11-04-2026 |
| Revenue: | $726,437,000 | Revenue Growth: | 40.45% |
| Revenue Growth (this year): | 19.55% | Revenue Growth (next year): | 13.34% |
| P/E Ratio: | 34.47 | Index: | |
| Free Cash Flow: | 105.1M | FCF Growth: | -58.55% |
SEC 8-K filings with transcript text
Nov 4, 2026 · 100% conf.
1D
+5.04%
$22.55
Act: -1.07%
5D
+12.16%
$24.08
20D
+10.16%
$23.65
2 acad-ex99_1.htm
Exhibit 99.1
Acadia Pharmaceuticals Reports Third Quarter 2026 Financial Results
- Third quarter GAAP total revenues of $342 million, up 22% year-over-year as compared to non-GAAP adjusted total revenues
- Third quarter DAYBUE® GAAP net sales of $140 million, up 39% year-over-year driven by strong uptake of DAYBUE STIX
- Third quarter NUPLAZID® GAAP net sales of $202 million, up 12% year-over-year on a non-GAAP adjusted basis
- Raises 2026 DAYBUE net sales guidance to $505–$520 million; narrows NUPLAZID range and total revenue range
- Additional data from Phase 3-enabling RADIANT Phase 2 Study to be presented at the Clinical Trials on Alzheimer’s Disease conference on November 17
SAN DIEGO, CA, November 4, 2026 – Acadia Pharmaceuticals Inc. (Nasdaq: ACAD), today announced its financial results for the third quarter ended September 30, 2026.
“Acadia delivered a strong third quarter, with total revenues of $342 million and continued commercial momentum across DAYBUE and NUPLAZID,” said Catherine Owen Adams, Chief Executive Officer of Acadia. “In the U.S., DAYBUE delivered another strong quarter, supported by meaningful uptake of DAYBUE STIX. In Europe, we are excited to build momentum following our recent launch of DAYBU in Germany. NUPLAZID also performed well, driven by underlying demand and the continued expansion of our commercial reach. Together, these growing franchises provide the commercial and financial foundation to advance clinical programs with the potential to become Acadia’s next meaningful growth opportunities. In Alzheimer’s disease psychosis, we are continuing Phase 3 development of remlifanserin based on Phase 2 results. As we look ahead to 2027, we anticipate two Phase 2 readouts: ACP-211 in major depressive disorder, and remlifanserin in Lewy body dementia psychosis, for which we are providing timing guidance for the first time. We look forward to sharing these updates as we continue to advance the next wave of our pipeline.”
Company Updates
• Announced Phase 3-enabling topline results from the Phase 2 RADIANT study of remlifanserin in Alzheimer’s disease psychosis, with consistent efficacy trends at the 60 mg dose across all four psychosis scales that were assessed for the full study population and a favorable safety and tolerability profile supporting continued and optimized Phase 3 development. Additional data will be presented at the Clinical Trials on Alzheimer’s Disease conference on November 17, 2026, in Boston.
• Two Phase 2 readouts anticipated in 2027: ACP-211 in major depressive disorder (MDD) in the second half and, for the first time, guidance for remlifanserin in Lewy body dementia Psychosis (LBDP) in the fourth quarter.
• Received FDA Fast Track designation for remlifanserin for the treatment of Lewy body dementia psychosis, recognizing the significant unmet need for new treatment options.
• Received allowance of a new U.S. patent covering weight-banded dosing of trofinetide, extending U.S. patent protections for DAYBUE and DAYBUE STIX by nearly five years, through March 2041.
• Received European Commission approval for DAYBU® (trofinetide) as the first and only treatment for the neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older in the European Union in August 2026 and launched DAYBU in Germany in early October 2026 with patients already receiving commercial product.
• Completed the Phase 3 study of trofinetide in Rett syndrome in Japan, with results consistent with the LAVENDER Phase 3 study and supportive of a planned regulatory filing; Acadia continues to pursue a distribution partner in preparation for regulatory filing in 2027 and a potential launch in 2028, subject to regulatory approval.
Financial Results
Revenues
GAAP total revenues, consisting of net product sales from NUPLAZID and DAYBUE, were $342 million in the third quarter of 2026, up 23% as compared to GAAP total revenues of $279 million in the third quarter of 2025, and up 22% as compared to non-GAAP adjusted total revenues of $281 million in the third quarter of 2025.
GAAP net product sales of NUPLAZID were $202 million in the third quarter of 2026, up 14% as compared to GAAP net product sales of $178 million in the third quarter of 2025, and up 12% as compared to non-GAAP adjusted net product sales of $180 million in the third quarter of 2025.
Net product sales of DAYBUE were $140 million in the third quarter of 2026, an increase of 39% as compared to $101 million in the third quarter of 2025.
A reconciliation of NUPLAZID non-GAAP adjusted net product sales and non-GAAP adjusted total revenues is provided in Table 1. A description of these adjustments is included under ‘Non-GAAP Financial Measures.’
Research and Development
Research and development expenses in the third quarter of 2026 were $76 million, as compared to $88 million for the same period of 2025.
Selling, General and Administrat
Aug 4, 2026 · 100% conf.
1D
+5.00%
$28.51
Act: +6.08%
5D
+12.80%
$30.63
20D
+10.78%
$30.08
2 acad-ex99_1.htm
Exhibit 99.1
Acadia Pharmaceuticals Reports Second Quarter 2026 Financial Results
- Second quarter DAYBUE® GAAP net sales of $125 million, up 30% year-over-year driven by strong uptake of DAYBUE STIX
- Second quarter NUPLAZID® GAAP net sales of $183 million, up 10% year-over-year on a non-GAAP adjusted basis
- Increased full year 2026 total revenue guidance to $1.24 to $1.30 billion, reflecting higher DAYBUE guidance of $480 to $510 million and reaffirmed NUPLAZID guidance of $760 to $790 million
- Topline results from the Phase 2 remlifanserin study in Alzheimer’s disease psychosis anticipated September to October 2026
SAN DIEGO, CA, August 4, 2026 – Acadia Pharmaceuticals Inc. (Nasdaq: ACAD), today announced its financial results for the second quarter ended June 30, 2026.
“Acadia delivered an outstanding second quarter, highlighted by strong commercial execution across both DAYBUE and NUPLAZID, resulting in total revenue growth of 17% year-over-year on an adjusted basis,” said Catherine Owen Adams, Chief Executive Officer of Acadia. “For DAYBUE, continued patient demand and robust uptake of STIX drove another quarter of strong performance. For NUPLAZID, we continued to see strong momentum, especially in new-to-brand prescriptions as our recently expanded sales force gained traction in the field. We remain confident that both franchises are on track to achieve our long-term ambition of approximately $1.7 billion in annual net sales in 2028. Looking ahead, we are excited about the anticipated topline results from our Phase 2 program evaluating remlifanserin in Alzheimer's disease psychosis in the September to October timeframe, which we believe represents a potentially transformational opportunity for Acadia.”
Company Updates
• Completed enrollment in the Phase 2 portion of the RADIANT program evaluating remlifanserin in Alzheimer's disease psychosis and initiated Phase 3 screening and enrollment; topline Phase 2 results are expected in September to October 2026.
• Received FDA Fast Track designation for remlifanserin for the treatment of hallucinations and delusions associated with Alzheimer's disease psychosis, recognizing its potential to address a significant unmet medical need.
• The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion recommending marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If approved by the European Commission, DAYBU would become the first authorized treatment for Rett syndrome in the European Union.
Financial Results
Revenues
GAAP total revenues, comprised of net product sales from NUPLAZID and DAYBUE, were $308 million for the second quarter of 2026, up 16% as compared to GAAP total revenues of $265 million in
the second quarter of 2025, and up 17% as compared to non-GAAP adjusted total revenues of $262 million in the second quarter of 2025.
GAAP net product sales of NUPLAZID were $183 million for the second quarter of 2026, up 9% compared to GAAP net product sales of $168 million for the second quarter of 2025, and up 10% as compared to non-GAAP adjusted net product sales of $166 million for the second quarter of 2025.
Net product sales of DAYBUE were $125 million for the second quarter of 2026, an increase of 30% as compared to $96 million for the second quarter of 2025.
A reconciliation of NUPLAZID non-GAAP adjusted net product sales and non-GAAP adjusted total revenues is provided in Table 1. A description of these adjustments is included under ‘Non-GAAP Financial Measures.’
Research and Development
Research and development expenses for the second quarter of 2026 were $82 million, compared to $78 million for the same period of 2025.
Selling, General and Administrative
Selling, general and administrative expenses for the second quarter of 2026 were $160 million, compared to $134 million for the same period of 2025.
Net Income
For the second quarter of 2026, Acadia reported net income of $32 million, or $0.18 per diluted share, compared to a net income of $27 million, or $0.16 per diluted share, for the same period in 2025.
Cash and Investments
At June 30, 2026, Acadia’s cash, cash equivalents, and investment securities totaled $956 million, compared to $820 million at December 31, 2025.
Full Year 2026 Financial Guidance (GAAP):
Acadia is updating its 2026 guidance:
• Total revenues revised to a range of $1.24 to $1.30 billion, up from the previous range of $1.22 to $1.28 billion.
• NUPLAZID net product sales in the range of $760 to $790 million.
• DAYBUE (including all forms of trofinetide) global net product sales in the range of $480 to $510 million, up from the previous range of $460 to $490 million.
• R&D expense in the range of $355 to $380 million, down from the previous range of $385 to $410 million.
•
May 6, 2026 · 100% conf.
1D
+4.99%
$22.55
Act: +5.05%
5D
+14.71%
$24.64
Act: +3.26%
20D
+12.71%
$24.21
Act: +1.12%
SEC.gov | Request Rate Threshold Exceeded
U.S. Securities and Exchange Commission
You’ve Exceeded the SEC’s Traffic Limit
Your request rate has exceeded the SEC’s maximum allowable requests per second. Your access to SEC.gov will be limited for 10 minutes.
Current guidelines limit each user to a total of no more than 10 requests per second, regardless of the number of machines used to submit requests. To ensure that SEC.gov remains available to all users, we reserve the right to block IP addresses that submit excessive requests.
The block will be lifted automatically by waiting 10 minutes. Continuing to exceed the SEC’s maximum allowable request rate during the time-out period will extend the duration of the time-out period. To ensure fair access for all users, please reduce the rate of your requests and visit SEC.gov again after the 10 minute time-out period has passed.
For best practices on efficiently downloading information from SEC.gov, including the latest EDGAR filings, visit sec.gov/developer. You can also sign up for email updates on the SEC open data program, including best practices that make it more efficient to download data, and SEC.gov enhancements that may impact scripted downloading processes. For more information, contact opendata@sec.gov.
For more information, please see the SEC’s Web Site Privacy and Security Policy. Thank you for your interest in the U.S. Securities and Exchange Commission.
Reference ID: 0.ce06d217.1784377399.ab79e539
More Information
Internet Security Policy
By using this site, you are agreeing to security monitoring and auditing. For security purposes, and to ensure that the public service remains available to users, this government computer system employs programs to monitor network traffic to identify unauthorized attempts to upload or change information or to otherwise cause damage, including attempts to deny service to users.
Unauthorized attempts to upload information and/or change information on any portion of this site are strictly prohibited and are subject to prosecution under the Computer Fraud and Abuse Act of 1986 and the National Information Infrastructure Protection Act of 1996 (see Title 18 U.S.C. §§ 1001 and 1030).
To ensure our website performs well for all users, the SEC monitors the frequency of requests for SEC.gov content to ensure automated searches do not impact the ability of others to access SEC.gov content. We reserve the right to block IP addresses that submit excessive requests. Current guidelines limit users to a total of no more than 10 requests per second, regardless of the number of machines used to submit requests.
If a user or application submits more than 10 requests per second, further requests from the IP address(es) may be limited for a brief period. Once the rate of requests has dropped below the threshold for 10 minutes, the user may resume accessing content on SEC.gov. This SEC practice is designed to limit excessive automated searches on SEC.gov and is not intended or expected to impact individuals browsing the SEC.gov website.
Note that this policy may change as the SEC manages SEC.gov to ensure that the website performs efficiently and remains available to all users.
Note: We do not offer technical support for developing or debugging scripted downloading processes.
See how ACAD stacks up against similar companies in the market
Enhance your trading experience with our free tools
The information presented on this page, "ACAD ACADIA Pharmaceuticals Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.